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The goal of the research was to determine the ability of new nanocomposite preparation EMAP II (endothelial monocyte activating poplypeptide II) to affect the expression of the tumor-necrosis factor and interferon in vitro. In the experiments, the transformed cell line L929 cells was used. The induced interferon levels were determined in samples of culture medium by the microtitration method in the L929 cell culture against test virus vesicular stomatitus VSV. Toxicity of the substance was assessed by its maximum tolerated dose. The amount of endotoxins in nanocomposite preparation EMAP II was measured using gel-clot test. The range of concentrations of EMAP II causing the production of tumor necrosis factor was determined. The concentration of lipopolysaccharides in the tested nanocomposite preparation was less then 0.5 IEU/kg. New nanocomposite preparation EMAP II has the ability to induce TNF-α production at rather low concentration 1.56-25.00 μg/ml (82.49-1370.00 mol х 10 -12
). The interferon production under the influence of nanocomposite preparation EMAP II was not found. The results support the application of the target nanocomposite reparation EMAP II for cancer treatment. 
